EC
MBX

Elmind Capital’s MBX Biosciences MBX Stock Holding History

Elmind Capital’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.02M Sell
91,000
-120,000
-57% -$4.19M 1.26% 20
2026
Q1 		$6.3M Hold
211,000
– – 1.79% 17
2025
Q4 		$6.65M Buy
+211,000
New +$5.12M 1.96% 16

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Elmind Capital's MBX Position: Q2 2026 in Review

Elmind Capital reduced its MBX Biosciences (MBX) stake by 57% in Q2 2026, selling an estimated $4.19M and leaving 91,000 shares worth $5.02M. The position accounts for 1.26% of the portfolio, ranked #20.

Elmind Capital first reported a position in MBX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.65M in Q4 2025. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Elmind Capital held 91,000 shares of MBX Biosciences worth $5.02M as of Q2 2026.
  • Elmind Capital sold 120,000 MBX Biosciences shares in Q2 2026, an estimated $4.19M.
  • MBX Biosciences made up 1.26% of Elmind Capital's portfolio in Q2 2026, its #20 holding.
  • Elmind Capital first reported a position in MBX Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Elmind Capital's MBX Biosciences position peaked at $6.65M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.